Financial News Discussion of CELG - Celgene Corporation on Mad Money

Financial News for Celgene Corporation (CELG)

CELG	2/9/2010 2:18PM	52 Week Price Range	Market Capitalization	Dividend Yield	Recent Dividend
CELG	$55.55	$36.90 — $59.67	$25.2 Billion	n/a	n/a

Want to Sharpen Your Investing?

Learn how Ockham can help investors make informed decisions and slice through the noise. Learn more about Ockham's services.

Explore Why Ockham?

Quality Analysis

Ockham has fundamental valuations on over 5000 companies which we distribute, to our clients via highly-focused equity reports, weekly newsletters, and analysts' daily market commentary blogs. (Learn More)

Crowd Sentiment

Through our partnership with The Motley Fool, Ockham provides the most robust data on investors' sentiment of individual stocks. This indicator, along with our valuations and our news tracking, helps our clients make informed investment decisions. (Learn More)

Financial News Slicing

With the influx of noise in our lives, it can be exceedingly difficult to separate the essential news from everything else. Ockham's RazorWire tool "slices" through business television and impactful blogs to provide you with the clearest information possible. (Learn More)

Celgene Corp. was discussed on Mad Money which was originally produced by CNBC on 11/3/2009

Celgene Corporation was talked about on Mad Money, and you can see the relevant discussion below.

Celgene Corporation is in the news. Find out how this impacts CELG trading on Ockham Research.

Thesis you're going to get a chance to make what I think is going to be a terrific trade, not an investment, a trade ahead of the annual american society of hematology meeting. That's december 5th. Write that down. CELGENE's going to be presenting some terrific revlimid data on you got that? Again, no hurry, though. I wouldn't pull the trigger on this trade until the week before the conference. CELGENE is a fabulous biotech company with a terrific slate of drugs for fighting cancer, especially revlimid. I even think it could be a takeover target for bigger pharma player looking to expand its oncology business. But as dan fitzpatrick's chart shows us, you don't have to buy it right here. Let it fill in the gap. You could buy some now if you really wanted, but I would much prefer you wait for a pullback

“rrific revlimid data on you got that? Again, no hurry, though. I wouldn't pull the trigger on this trade until the week before the conference. CELGENE is a fabulous biotech company with a terrific slate of drugs for fighting cancer, especially revlimid. I even think it could be a takeover target for bigger pharma player looking to expand its oncology business. But as dan fitzpatrick's chart shows us, you don't have to buy it right here. Let it fill in the gap. You could buy some now if you really wanted, but I would much prefer you wait for a pullback ” Mad Money Nov 3, 2009 6:35 PM

Just a couple of things to take note of:

Since the stock was mentioned on Mad Money on Tuesday, November 03, 2009 the price of CELG shares has increased 10.48%.
Jim Cramer mentioned quite a few stocks, 28 individual companies to be exact. You can see the all company slices for Mad Money on the recap page.
There were 8 mentions of CELG on just this episode. You can see the all company slices of those on the Mad Money recap page.
CELG has had 21 mentions, on various business television shows, since this one. Find out what was said with the latest financial news on Celgene Corporation.
The most active stock on Mad Money over the last 2 weeks has been Apple, Incorporated.